Ginkgo biloba-EGb 761 / AntiAg Cancer Research Results

EGb 761, Ginkgo biloba-EGb 761: Click to Expand ⟱

Features:

<p>
<strong>EGb 761</strong> is a standardized, purified extract of
<em>Ginkgo biloba</em> leaves developed for medicinal use. It is typically
standardized to approximately <strong>22–27% flavone glycosides</strong> and
<strong>5–7% terpene lactones</strong>, including ginkgolides A, B and C and
bilobalide, while potentially undesirable <strong>ginkgolic acids</strong> are
reduced to very low levels. EGb 761 has antioxidant, mitochondrial,
neuroprotective, vasoregulatory, anti-inflammatory and platelet-activating-factor
antagonist effects and has been studied extensively in cognitive impairment,
dementia and Alzheimer’s disease. Reported mechanisms include reduction of
oxidative stress, stabilization of mitochondrial function, modulation of
neurotransmitter signalling, protection against amyloid-β-associated toxicity,
improved cerebral microcirculation and modulation of inflammatory pathways.
EGb 761 is kept separate from generic <em>Ginkgo biloba</em> supplements
because commercial extracts vary substantially in flavonoid, terpene-lactone
and ginkgolic-acid content and are not necessarily pharmacologically equivalent
to the standardized EGb 761 preparation. EGb 761 is kept separate
from isolated ginkgolides, bilobalide and ginkgolic acids 
</p>

<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12417213/">high PCA content in EGb 761 may contribute to cognitive benefits</a><br>
 bioactive compounds such as terpenoids (Ginkgolides A, B, and C), polyphenols, organic acids, and flavonoids (quercetin, kaempferol, and isorhamnetin). <br>

<a href="https://pubmed.ncbi.nlm.nih.gov/22784423/">EGb 761</a> 
is a dry extract from Ginkgo biloba leaves (35–67:1), extraction solvent acetone
60% (w/w). The extract is adjusted to 22.0–27.0% ginkgo flavonoids and 5.0–7.0% terpene lactones,
consisting of 2.8–3.4% ginkgolides A, B, and C and 2.6–3.2% bilobalide and contains less than 5 ppm
ginkgolic acids<br>

<pre>


Table 1. Protective capacity of individual compounds of EGb 761 in brain cells)
COMPOUNDMEAN (SEM) PROTECTION ( % )
(0.5 mg/ml) (percentage recovery after insult)
Ginkgolide A    8.0±1.9∗∗
Ginkgolide B    33.0±11.2∗
Ginkgolide C    8.5±1.6∗∗
Ginkgolide J    37.0±12.2∗
Bilobalide      36.3±7.7∗∗
Flavonoids      56.4±12.7∗∗∗
</pre>

AntiAg, Antiplatelet aggregation: Click to Expand ⟱

Source:

Type:

Antiplatelet aggregation refers to the process by which platelets clump together to form a blood clot.
The plethora of evidence indicates that among multiple hemostasis components, platelets play major roles in cancer progression by providing surface and granular contents for several interactions as well as behaving like immune cells.On the other hand, there are suggestions that antiplatelet treatment may promote solid tumor development in a phenomenon described as “cancers follow bleeding.” The controversies around antiplatelet agents justify insight into the subject to establish what, if any, role platelet-directed therapy has in the continuum of anticancer management.
The interplay between antiplatelet aggregation and cancer is an area of active research, with potential implications for therapeutic strategies. Antiplatelet agents, such as aspirin, are being investigated for their role in cancer prevention and treatment, particularly in reducing metastasis and improving patient outcomes.

Scientific Papers found: Click to Expand⟱

7241-

EGb 761,

ASA,

Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial

Trial,

Nor,

*Dose↝, (EGb 761, 300 mg/day) was compared with placebo for effects on measures of platelet aggregation among adults consuming 325 mg/day aspirin in a randomized, double-blind, placebo-controlled
*AntiAg∅, In conclusion, in older adults with PAD or cardiovascular disease risk, a relatively high dose of Ginkgo biloba combined with 325 mg/day daily aspirin did not have a clinically or statistically detectable impact on indices of coagulation examined ove

7228-

EGb 761,

Current Perspectives on the Beneficial Role of Ginkgo biloba in Neurological and Cerebrovascular Disorders

Review,

AD,

*Dose↝, A standardized formulation, EGb 761®, also sold as Tanakan® or Tebonin®, was created to normalize the constituents to assure reliable and consistent drug performance and the absence of ginkgolic acid, a known allergen naturally found in Ginkgo
*PAF↑, Ginkgolides have been clinically shown to act as platelet-activating factor (PAF) antagonists, inhibiting platelet aggregation and promoting increased blood flow.
*AntiAg↑,
*BloodF↑,
*Inflam↓, Additionally, BB(bilobalide) has shown anti-inflammatory properties and neuroprotection in preclinical models of stroke16 and AD
*neuroP↑,
*Stroke↓, Alternatively, promising results have been observed that support administration of EGb 761 soon after the onset of ischemia and during the recovery period.
*Dose↝, The standard clinical dose of EGb 761 is 120 mg (~1.7 mg/kg) once or twice daily; thus, a standard dose will contain ~3–4 mg ginkgolides A, B, and C, 3–4 mg BB, and 29 mg flavonoids.
*Sepsis↓, Patients treated with antimicrobials plus GB showed a significant drop in mortality as compared to patients treated with antimicrobials and placebo; this finding led to the development of other PAF antagonists for the treatment of sepsis
*memory↑, when administered daily, EGb 761 (240 mg daily) may improve some aspects of memory better than others

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:

Total Targets: 0

Pathway results for Effect on Normal Cells:

Infection & Microbiome(tgid=24) ⓘ

Sepsis↓, 1,
Total Targets: 10

Scientific Paper Hit Count for: AntiAg, Antiplatelet aggregation

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:438  Target#:10  State#:%  Dir#:%
  wNotes=on  sortOrder:rid,rpid

Ginkgo biloba-EGb 761 / AntiAg Cancer Research Results

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

NA, unassigned(tgid=0) ⓘ

Migration(tgid=13) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Clinical Biomarkers(tgid=22) ⓘ

Functional Outcomes(tgid=23) ⓘ

Infection & Microbiome(tgid=24) ⓘ

Home Page